Disclosed are 2-(indazol-3-ylamino)-benzimidazole derivatives as represented by the general formula (I), wherein: R1 is an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl each of a, a, b, and c is independently N or C(H) each of R5 and R6 is independently H, acyl, halo, hydroxy, amino, nitro, cyano, guanadino, amidino, carboxy, sulfo, mercapto, sulfanyl, sulfinyl, sulfonyl, sulfonamide, amido, sulfamide, urea, thiourea, carbamoyl, cycloalkyl, cycloalkenyl, cycloalkyloxy, heterocycloalkyl, optionally substituted heterocycloalkenyl, heterocycloalkyloxy, aryl, arylalkyl, aryloxy, aroyl, optionally substituted heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaroyl R4 is H K is -N(H)- J is a bond, optionally substituted alkylene, -C(O)-, -C(O)-O-, -C(O)-N(H) n is 0 or 1 and p is 1, 2, 3, or 4. Representative compounds include (2-(5-(3-aminophenyl)-1H-indazol-3-ylamino)-1-cyclohexyl-1H-benzo[d]imidazol-6-yl)methanol, (1-(4-hydroxycyclohexyl)-2-(5-(2-methoxyphenyl)-1H-indazol-3-ylamino)-1H-benzo[d]imidazol-5-yl)(pyrrolidin-1-yl)methanone and 1-(4-hydroxycyclohexyl)-N-isopentyl-2-(5-(2-methoxyphenyl)-1H-indazol-3-ylamino)-1H-benzo[d]imidazole-5-carboxamide. Further disclosed is a pharmaceutical composition which comprises a pharmaceutically acceptable carrier or excipient and a compound as defined above for treating rheumatoid arthritis, multiple sclerosis, sepsis, osteoarthritis, inflamm
